In 2015, over 25 years after it was initially approved in France, Canada became the latest country to approve Mifepristone, the first drug indicated for medical abortion in the first trimester. This has provided a much-needed option for many patients and is changing the landscape for first trimester abortions. However rollout has been slow, and access still remains an issue for patients across the province, with many having to travel long distances to find a provider. This presentation aims to improve access by arming practitioners with the knowledge and resources to be able to provide medical abortion for their patients in a safe, patient-centred and evidence-based manner.
Bay Centre for Birth Control, Women's College Hospital
Dr Sarah Warden is a Family Physician working in Sexual and Reproductive Health at the Bay Centre for Birth Control where she is the Lead Physician for the Mifepristone Medical Abortion Program. Sarah completed her Family Medicine Residency at the University of Toronto, Women’s College Hospital site. Prior to her medical training, Sarah completed a Master’s degree examining the sex differences in response to psychiatric medications, in particular sexual side effects.
Sarah has always been passionate about women’s health with a focus on reproductive rights and the intersection of sexual health and self-worth.
Further to this goal, Sarah is proud to also practice general Family Medicine at the University of Toronto Student Health and Wellness Clinic where she has a special interest in the care of transgender and genderqueer patients.
Friday, November 24
8:00 AM – 9:00 AM
The asset you are trying to access is locked. Please enter your access key to unlock.